Team
Pawel Zolnierczyk- Chief Executive Officer
Pawel is cofounder and Director of iQure Pharma Inc. A physicist and business manager by training, Pawel is driven entrepreneur which successfully set-up and managed university oncology focused spin-off Onco-NX Ltd sold in 2014. Pawel successfully managed new therapeutics and diagnostics inventions including exits via license to global pharma with commercial value of double digits millions of dollars. Pawel raised over $12M for early stage companies from the Business Angels, Venture Capital and Charity organisations. Between 2014 and 2018 Pawel served as IP and R&D Manager and later as a Chief Operating Officer in UK based oncology focused business Incanthera Ltd. During this time, he has been responsible for portfolio of over 100 patents and 4 new therapeutics drugs in preclinical and early clinical stage of development. Pawel is a graduate of the Gdansk University of Technology (PL) – Physics and The University of Salford (UK) – Master of Enterprise Technology (Hons).
Henk de Wilde - Chief Operating Officer
A pharmacist by training, Henk started in 1988 as project Leader in a Phase I Clinical Research organization, where he as senior manager helped build up the company to the largest Phase I unit in the world. After eight years, Henk then was asked to join Roche as Project Leader for CNS and worked several years in Clinical Development, during which he in parallel set up and managed the procurement office for Clinical Operations, responsible for all global outsourcing activities. In 1998, Henk was. In the fortunate position to be responsible for the clinical development execution of Herceptin and its successful launch in Metastatic and Adjuvant Breast Cancer and Gastric Cancer.
In 2001 Henk was asked to create and head a cross-functional matrix unit dedicated to oncology development and participated in multiple due diligence activities for new oncology compounds.
From 2007 onward, Henk got more involved in Business Process Improvements and was responsible for the global implementation of A Clinical Trial Management System, a Trial Master File System and a Safety Document Distribution System. In addition, he was involved in the development of two commercially available patient recruitment forecasting systems.
Since leaving Roche in 2017, Henk has been involved in the successful launch of three companies in venture capital, IT and business process optimization for life science.
In 2018 he joined Widler & Schiemann as Managing Director Europe supporting small and midsize pharma and biotech companies in their drug development of new medications.
In 2019 Henk and five colleagues founded iQure Pharma to develop novel medications sourced from Universities and independent researchers.
Marcin Majewski - Chief Financial Officer
Pawel is cofounder and Director of iQure Pharma Inc. A physicist and business manager by training, Pawel is driven entrepreneur which successfully set-up and managed university oncology focused spin-off Onco-NX Ltd sold in 2014. Pawel successfully managed new therapeutics and diagnostics inventions including exits via license to global pharma with commercial value of double digits millions of dollars. Pawel raised over $12M for early stage companies from the Business Angels, Venture Capital and Charity organisations. Between 2014 and 2018 Pawel served as IP and R&D Manager and later as a Chief Operating Officer in UK based oncology focused business Incanthera Ltd. During this time, he has been responsible for portfolio of over 100 patents and 4 new therapeutics drugs in preclinical and early clinical stage of development. Pawel is a graduate of the Gdansk University of Technology (PL) – Physics and The University of Salford (UK) – Master of Enterprise Technology (Hons).
Beat Widler - Chief Compliance Officer
Dr. Widler, a Ph.D. graduate from the Swiss Federal Institute of Technology (ETHZ) in Zurich, and holds the Swiss Diploma of Pharmaceutical Medicine.
He operates as an independent CQA, Quality Risk Management, GCP & Pharmacovigilance Auditing Expert and is Managing Partner at Widler & Schiemann AG (www.wsqms.com) in Zug Switzerland.
Over his 35 years long career in the pharma industry he built his extensive knowledge in the field of clinical development. From 1986 till 2012 Dr. Widler worked for Hoffmann-La Roche first as an International Drug Regulatory Affairs officer, then as a Senior Clinical Research Scientist. In 1993 he then joined the International Clinical Quality Assurance department. From 1997 to 2011 he was the Global Head of the Department for Quality, Ethics and Systems’ in Roche Pharma. In 2012 he founded together with Dr. Peter Schiemann Widler & Schiemann Ltd., a Management Consulting firm specialized in supporting their clients in quality management and drug development of new medications.
Dr. Widler is an active member in a variety of international GCP working parties and he regularly lectures at DIA, EFGCP, WHO, ECPM (University Basel) seminars. In the areas of quality risk management and Quality by Design he was an active member of the CTTI (Clinical Trials Transformation Initiative) and OECD working groups. He is a founding member of ACRES – the Alliance for Clinical Research Excellence and Safety(www.acresglobal.net), founding member of the midata cooperative (http://www.datenundgesundheit.ch) and a faculty member of Basel University.
Jon Doe - Chief Business Officer
Marcin has significant experience in conducting investment transactions, investment project evaluation, valuation of companies, strategic advice, commercialization of business projects in the early stages of development as well as company management.
Marcin has 13 years of experience in Private Equity and Venture Capital market, including more than 16 years with companies in the seed-, start-up and expansion phase in the area of new technologies. In 2006-2012 Marcin was related with the BBI Capital S.A. Private Equity Investment Group, where in 2008 he initiated and created a Venture Capital Fund (as a subsidiary company) – the BBI Seed Fund (currently IMPERA Seed Fund) founded together with the National Capital Fund (www.kfk.org.pl). In 2008-2012 Marcin was one of the key Investment Managers at the VC BBI Seed Fund responsible for deal flow generation, investments and investment fund management. He was member of the Management Board and Member of the Investment Committee. In addition he was also member of the Supervisory Board of six portfolio companies. His industry experience ranges from IT to Mobile Communication, Health Care, Medical Devices, Telemedicine, Biotech, Travel, TMT (Telecom, Media, Technology), ICT (Information and Communication Technologies), FMCG (Fast-Moving Consumer Goods) and Advertising.
From 2014 Managing Partner and Investment Manager at Smart Money Investment Fund – Business Ideas (www.businessideas.pl) supporting start-up companies to achieve maturity and business success, providing them with management skills, investors and/or collaboration partners.
In 2019 Marcin and five colleagues founded iQure Pharma to develop novel medications sourced from Universities and independent researchers.
Anna Rzewuska - Chief Financial Officer and Investor Relations
For more than 10 years Anna was the Investment Manager of the VC fund of funds in Poland – National Capital Fund. She has experience in originating the VC funds, structuring the transactions, negotiation of investment agreements, valuations, investment, business and legal aspects of VC transactions and start-ups. She has supervised 6 VC funds of an average AUM of EUR20m. She was an Investment Committee Member and Supervisory Board Member at those funds in different time periods.
Prior to that she has been working in financial consulting (valuations of enterprises, advanced financial modelling in Excel, IPOs) for Deloitte and BRE Corporate Finance in Poland.
By training she obtained specialization in Pharma-Biotech Product & Company Valuation. In 2014 she conducted series of valuations of innovative biotech product candidates for the International Institute of Molecular and Cell Biology in Warsaw.
In 2019 Anna and five colleagues founded iQure Pharma to develop novel medications sourced from Universities and independent researchers.